Hide metadata

dc.date.accessioned2020-12-08T20:23:04Z
dc.date.available2020-12-08T20:23:04Z
dc.date.created2020-12-03T09:10:12Z
dc.date.issued2020
dc.identifier.citationBinde, Caroline Ditlev Tvete, Ingunn Fride Gåsemyr, Jørund Inge Natvig, Bent Klemp, Marianne . Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson’s disease: a multiple treatment comparison meta-analysis. European Journal of Clinical Pharmacology. 2020, 76(12), 1731-1743
dc.identifier.urihttp://hdl.handle.net/10852/81476
dc.description.abstractAbstract Purpose To investigate the comparative effectiveness of dopamine agonists and monoamine oxidase type-B (MAO-B) inhibitors available for treatment of Parkinson’s disease. Methods We performed a systematic literature search identifying randomized controlled trials investigating 4 dopamine agonists (cabergoline, pramipexole, ropinirole, rotigotine) and 3 MAO-B inhibitors (selegiline, rasagiline, safinamide) for Parkinson’s disease. We extracted and pooled data from included clinical trials in a joint model allowing both direct and indirect comparison of the seven drugs. We considered dopamine agonists and MAO-B inhibitors given as monotherapy or in combination with levodopa. Selected endpoints were change in the Unified Parkinson’s Disease Rating Scale (UPDRS) score, serious adverse events and withdrawals. We estimated the relative effectiveness of each dopamine agonist and MAO-B inhibitor versus comparator drug. Results Altogether, 79 publications were included in the analysis. We found all the investigated drugs to be effective compared with placebo when given as monotherapy except safinamide. When considering combination treatment, the estimated relative effects of selegiline, pramipexole, ropinirole, rotigotine, cabergoline, rasagiline and safinamide were 2.316 (1.819, 2.951), 2.091 (1.889, 2.317), 2.037 (1.804, 2.294), 1.912 (1.716, 2.129), 1.664 (1.113, 2.418), 1.584 (1.379, 1.820) and 1.179 (1.031, 1.352), respectively, compared with joint placebo and levodopa treatment. Conclusions Dopamine agonists were found to be effective as treatment for Parkinson’s disease, both when given as monotherapy and in combination with levodopa. Selegiline and rasagiline were also found to be effective for treating Parkinson’s disease, and selegiline was the best option in combination with levodopa among all the drugs investigated.
dc.languageEN
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleComparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson’s disease: a multiple treatment comparison meta-analysis
dc.typeJournal article
dc.creator.authorBinde, Caroline Ditlev
dc.creator.authorTvete, Ingunn Fride
dc.creator.authorGåsemyr, Jørund Inge
dc.creator.authorNatvig, Bent
dc.creator.authorKlemp, Marianne
cristin.unitcode185,53,18,15
cristin.unitnameAvdeling for farmakologi
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2
dc.identifier.cristin1855611
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=European Journal of Clinical Pharmacology&rft.volume=76&rft.spage=1731&rft.date=2020
dc.identifier.jtitleEuropean Journal of Clinical Pharmacology
dc.identifier.volume76
dc.identifier.issue12
dc.identifier.startpage1731
dc.identifier.endpage1743
dc.identifier.doihttps://doi.org/10.1007/s00228-020-02961-6
dc.identifier.urnURN:NBN:no-84556
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn0031-6970
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/81476/1/Postnr%2B1855611_Binde_Klemp_2020_Article_ComparativeEffectivenessOfDopa.pdf
dc.type.versionPublishedVersion


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International